Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Xuqi Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2497-020X; OpenAlex author ID A5027770418. Sources: OpenAlex.

Their work

Papers
38 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2012: 4 papers · 2013: 4 papers · 2014: 6 papers · 2015: 6 papers · 2016: 5 papers · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers

Papers 38

  1. Identification and validation of a hypoxia- and immune-related prognostic signature for pancreatic cancer. Co-author DOI 10.1016/j.bbrep.2025.102205↗
  2. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Last author DOI 10.1186/s13062-025-00595-1↗
  3. Huaier extract restrains pancreatic cancer by suppressing Wnt/β-catenin pathway. Last author DOI 10.1016/j.biopha.2020.110126↗
  4. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Co-author DOI 10.1155/2020/1868764↗
  5. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  6. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Last author DOI 10.1111/cpr.12514↗
  7. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Last author DOI 10.1186/s13046-019-1288-7↗
  8. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  9. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Co-author DOI 10.1159/000494547↗
  10. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  11. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. Co-author DOI 10.3892/or.2018.6518↗
  12. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  13. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  14. Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. Co-author DOI 10.1155/2016/1616781↗
  15. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Co-author DOI 10.1155/2016/3897250↗
  16. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer. Co-author DOI 10.1155/2016/6815727↗
  17. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  18. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Co-author DOI 10.18632/oncotarget.7776↗
  19. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  20. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  21. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  22. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  23. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗
  24. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.5045↗
  25. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Co-author DOI 10.1016/j.canlet.2014.02.003↗
  26. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Co-author DOI 10.1016/j.febslet.2014.01.007↗
  27. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Last author DOI 10.1155/2014/546353↗
  28. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-3426↗
  29. Disrupting the balance between tumor epithelia and stroma is a possible therapeutic approach for pancreatic cancer. Co-author DOI 10.12659/msm.892523↗
  30. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗
  31. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0609↗
  32. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Co-author DOI 10.1186/1476-4598-12-66↗
  33. Biomarkers screening between preoperative and postoperative patients in pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.7.4161↗
  34. Aberrant expression of CXCR4 and β-catenin in pancreatic cancer. Co-author PMID 24023356↗
  35. Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer. First author DOI 10.1016/j.bbcan.2012.03.010↗
  36. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathw… Co-author DOI 10.1016/j.canlet.2012.02.035↗
  37. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Co-author DOI 10.2174/13816128112092395↗
  38. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Co-author DOI 10.2174/13816128112092404↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 35 shared papers, 2012–2025 · strength 2.07
  2. Qinhong Xu · 27 shared papers, 2012–2025 · strength 1.49
  3. Wanxing Duan · 28 shared papers, 2012–2020 · strength 1.47
  4. Jianjun Lei · 24 shared papers, 2012–2020 · strength 1.21
  5. Jiguang Ma · 21 shared papers, 2013–2020 · strength 1.18
  6. Zheng Wang · 20 shared papers, 2012–2020 · strength 1.12
  7. Zheng Wu · 14 shared papers, 2013–2025 · strength 0.92
  8. Erxi Wu · 18 shared papers, 2012–2020 · strength 0.82
  9. Cancan Zhou · 8 shared papers, 2017–2025 · strength 0.78
  10. Weikun Qian · 7 shared papers, 2018–2025 · strength 0.78
  11. Zhengdong Jiang · 13 shared papers, 2015–2019 · strength 0.75
  12. Liang Zong · 8 shared papers, 2015–2018 · strength 0.41
  13. Wei Li · 8 shared papers, 2013–2020 · strength 0.40
  14. Liang Cheng · 5 shared papers, 2018–2019 · strength 0.40
  15. Tao Qin · 4 shared papers, 2018–2020 · strength 0.38
  16. Liang Han · 7 shared papers, 2014–2020 · strength 0.38
  17. Zhenhua Ma · 7 shared papers, 2014–2017 · strength 0.32
  18. Xin Chen · 5 shared papers, 2015–2018 · strength 0.30
  19. Liankang Sun · 4 shared papers, 2017–2020 · strength 0.30
  20. Ying Xiao · 3 shared papers, 2018–2020 · strength 0.29
  21. Lun Zhang · 6 shared papers, 2015–2016 · strength 0.29
  22. Ligang Nan · 6 shared papers, 2015–2016 · strength 0.27
  23. Ganghua Yang · 1 shared paper, 2025 · strength 0.27
  24. Yong Wan · 1 shared paper, 2025 · strength 0.27
  25. Shuai Wu · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.